What is HC Wainwright’s Forecast for ORKA Q1 Earnings?

Oruka Therapeutics, Inc. (NASDAQ:ORKA) – Stock analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Oruka Therapeutics in a research note issued to investors on Monday, April 13th. HC Wainwright analyst M. Kapoor forecasts that the company will post earnings per share of ($0.63) for the quarter. HC Wainwright has a “Buy” rating and a $70.00 price objective on the stock. The consensus estimate for Oruka Therapeutics’ current full-year earnings is ($3.41) per share. HC Wainwright also issued estimates for Oruka Therapeutics’ Q2 2026 earnings at ($0.65) EPS, Q3 2026 earnings at ($0.70) EPS, Q4 2026 earnings at ($0.73) EPS, FY2026 earnings at ($2.71) EPS, Q1 2027 earnings at ($0.78) EPS, Q2 2027 earnings at ($0.83) EPS, Q3 2027 earnings at ($0.93) EPS, Q4 2027 earnings at ($1.01) EPS and FY2027 earnings at ($3.55) EPS.

A number of other equities research analysts also recently issued reports on ORKA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Thursday, January 22nd. Leerink Partners upped their price target on shares of Oruka Therapeutics from $58.00 to $86.00 and gave the stock an “outperform” rating in a report on Monday, March 16th. Wall Street Zen upgraded shares of Oruka Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, March 16th. Stifel Nicolaus lifted their price objective on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the company a “buy” rating in a research note on Friday, March 13th. Finally, UBS Group boosted their price objective on shares of Oruka Therapeutics from $50.00 to $75.00 and gave the company a “buy” rating in a research report on Monday, April 6th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $78.90.

Oruka Therapeutics Stock Performance

Shares of NASDAQ ORKA opened at $65.55 on Wednesday. The stock has a market capitalization of $3.25 billion, a P/E ratio of -35.24 and a beta of -0.54. The stock’s fifty day moving average is $41.37 and its 200 day moving average is $33.23. Oruka Therapeutics has a 52 week low of $8.31 and a 52 week high of $67.94.

Oruka Therapeutics (NASDAQ:ORKA) last released its earnings results on Thursday, March 12th. The company reported ($0.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.16.

Insider Transactions at Oruka Therapeutics

In other news, CEO Lawrence Otto Klein sold 1,729 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $41.30, for a total value of $71,407.70. Following the sale, the chief executive officer directly owned 927,309 shares in the company, valued at approximately $38,297,861.70. This trade represents a 0.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Joana Goncalves sold 7,641 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $40.91, for a total transaction of $312,593.31. Following the completion of the sale, the insider owned 33,377 shares in the company, valued at approximately $1,365,453.07. The trade was a 18.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 23,765 shares of company stock worth $1,089,745. Company insiders own 24.69% of the company’s stock.

Hedge Funds Weigh In On Oruka Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Fairmount Funds Management LLC boosted its position in Oruka Therapeutics by 9.9% in the third quarter. Fairmount Funds Management LLC now owns 3,705,262 shares of the company’s stock valued at $71,252,000 after buying an additional 333,340 shares in the last quarter. Viking Global Investors LP acquired a new position in shares of Oruka Therapeutics during the third quarter worth $51,280,000. Deep Track Capital LP lifted its stake in shares of Oruka Therapeutics by 38.4% in the 3rd quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock valued at $51,051,000 after acquiring an additional 735,983 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Oruka Therapeutics by 38.1% in the 4th quarter. Vanguard Group Inc. now owns 2,453,530 shares of the company’s stock valued at $74,366,000 after acquiring an additional 676,865 shares during the last quarter. Finally, RTW Investments LP boosted its holdings in shares of Oruka Therapeutics by 5.8% during the 4th quarter. RTW Investments LP now owns 2,058,148 shares of the company’s stock valued at $62,382,000 after acquiring an additional 112,499 shares in the last quarter. Institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics News Roundup

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Wedbush raised its price target to $85 and assigned an “outperform” rating, a notable bullish signal that increases upside expectations for ORKA. Wedbush raises ORKA target
• Positive Sentiment: BTIG boosted its price target to $78, adding further analyst-driven momentum that may support buying interest. BTIG raises ORKA target to $78
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and a $70 target while publishing multi‑quarter and FY2026–FY2027 EPS forecasts (FY2027: -$3.55), signaling continued analyst conviction despite losses; this sustained buy-side research supports the stock’s rally. HC Wainwright coverage
• Neutral Sentiment: An insider (Joana Goncalves) sold 7,000 shares under a pre‑arranged Rule 10b5‑1 plan, reducing her stake ~17.3%; because the sale was pre‑planned and disclosed via SEC Form 4, it’s less likely to signal new negative information, but it can still be perceived as supply pressure. SEC Form 4
• Negative Sentiment: Consensus and firm forecasts confirm continued multi‑year losses (consensus FY current year ~ -$3.41 EPS; HC Wainwright FY2027 -$3.55), which keeps valuation reliant on future clinical/ commercial successes and may cap multiple expansion despite high price‑target activity.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.